Lambert DM, Fowler CJ (2005). „The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications”. J. Med. Chem.48 (16): 5059–87. DOI:10.1021/jm058183t. PMID16078824.
Begg M, Pacher P, Bátkai S, Osei-Hyiaman D, Offertáler L, Mo FM, Liu J, Kunos G (2005). „Evidence for novel cannabinoid receptors”. Pharmacol. Ther.106 (2): 133–45. DOI:10.1016/j.pharmthera.2004.11.005. PMID15866316.
Morgan CJ, Curran HV (April 2008). „Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis”. The British journal of psychiatry : the journal of mental science192 (4): 306–7. DOI:10.1192/bjp.bp.107.046649. PMID18378995.
Russo EB, Burnett A, Hall B, Parker KK (August 2005). „Agonistic properties of cannabidiol at 5-HT1a receptors”. Neurochemical Research30 (8): 1037–43. DOI:10.1007/s11064-005-6978-1. PMID16258853.
Lambert DM, Fowler CJ (2005). „The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications”. J. Med. Chem.48 (16): 5059–87. DOI:10.1021/jm058183t. PMID16078824.
Begg M, Pacher P, Bátkai S, Osei-Hyiaman D, Offertáler L, Mo FM, Liu J, Kunos G (2005). „Evidence for novel cannabinoid receptors”. Pharmacol. Ther.106 (2): 133–45. DOI:10.1016/j.pharmthera.2004.11.005. PMID15866316.
Morgan CJ, Curran HV (April 2008). „Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis”. The British journal of psychiatry : the journal of mental science192 (4): 306–7. DOI:10.1192/bjp.bp.107.046649. PMID18378995.
Russo EB, Burnett A, Hall B, Parker KK (August 2005). „Agonistic properties of cannabidiol at 5-HT1a receptors”. Neurochemical Research30 (8): 1037–43. DOI:10.1007/s11064-005-6978-1. PMID16258853.